Munich-based Tubulis was set up in 2019 to address the current limitations of antibody drug conjugate technology and rapidly discover and develop novel ADCs. The company designs what CEO Dominik Schumacher describes as perfectly matched antibodies and payloads for particular diseases, based on the disease biology. The aim is to move the application of such products beyond cancer.
BIO-Europe Spring 2019: Newcomer Tubulis Tackles ADC Technology Shortcomings
Newly established Tubulis has been set up to generate protein-drug conjugates using a novel platform approach deriving from two German academic institutes. CEO Dominik Schumacher spoke to Mike Ward at BIO-Europe Spring 2019.
